{
  "data": {
    "asOf": "2026-10-30T22:25:44.806Z",
    "dedupMethod": "exact cross-registry identifier matching; probabilistic = review only",
    "byRegistry": {
      "clinicaltrials_gov": 1
    },
    "canonicalTrial": {
      "canonicalId": "NCT03392909",
      "title": "Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)",
      "scientificTitle": "Restoration of Full-Length Type VII Collagen in RDEB Patients With Nonsense Mutations After Intravenous Gentamicin Treatment",
      "status": "unknown",
      "studyType": "interventional",
      "phase": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recessive Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Gentamicin",
          "type": "DRUG",
          "description": "Short-term intravenous gentamicin therapy should have the advantage of treating all of the patient's multiple skin wounds simultaneously. Six patients (three adults and 3 children) will receive intravenous gentamicin (7.5 mgs/kg) daily for 14 days and then stopped. Three adult patients will receive intravenous gentamicin (7.5mg/kg) biweekly for three months and then stopped."
        }
      ],
      "sponsor": {
        "name": "University of Southern California",
        "type": "OTHER"
      },
      "locations": [
        {
          "city": "Los Angeles",
          "country": "United States",
          "facility": "University of Southern California"
        }
      ],
      "outcomes": {
        "other": [],
        "primary": [
          "Full-length type VII collagen expression",
          "Generation of anchoring fibrils",
          "Absence of gentamicin side effects"
        ],
        "secondary": [
          "Improved Disease Activity scores",
          "Improved Quality of Life score"
        ]
      },
      "eligibility": {
        "sex": "ALL",
        "criteria": "Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged 7 and up can participate in the 14 day IV gentamicin trial. Male or female, aged 18 and up can participate in the 3 month IV gentamicin trial.\n* Been diagnosed with recessive dystrophic epidermolysis bullosa (RDEB) and with a nonsense mutation in the COL7A1 gene.\n* Immunofluorescence evaluation of skin biopsies reveals absence or decreased intensity of C7 expression at their DEJ (dermal epidermal junction) compared with normal human skin biopsies.\n* Cultured fibroblasts from patient skin synthesize and secrete full-length, 290kDa C7 alpha chains in the presence of supplemented gentamicin (400 μg/ml in culture).\n* Ability to sit or lie down for over 30 minutes for IV infusions. For those in the 3 month trial, to be willing to continue treatment at home under the supervision of licensed and trained infusion nurses.\n\nExclusion Criteria:\n\n* Recent exposure to gentamicin within the past 6 weeks.\n* Pre-existing known auditory impairment.\n* Pre-existing known renal impairment.\n* Pre-existing known allergies to aminoglycosides or sulfate compounds.\n* Pregnancy or lactation\n* Current use of medications with known ototoxicity or nephrotoxicity.\n* Current enrollment in another experimental clinical trial involving systemic treatment with C7 or C7 producing products for the treatment of RDEB.",
        "minimumAge": "7 Years",
        "healthyVolunteers": false
      },
      "enrollment": {
        "type": "ESTIMATED",
        "count": 9
      },
      "startDate": "2018-07-05",
      "completionDate": "2023-12-01",
      "lastUpdated": "2022-11-03T00:00:00.000Z",
      "firstPosted": "2018-01-08T00:00:00.000Z",
      "resultsAvailable": false,
      "sourceRegistries": [
        "clinicaltrials_gov"
      ],
      "sourceUrls": [
        "https://clinicaltrials.gov/study/NCT03392909"
      ]
    },
    "identifiers": [
      {
        "idType": "nct",
        "idValue": "NCT03392909",
        "declaredBy": "clinicaltrials_gov"
      }
    ],
    "sourceRecords": [
      {
        "registry": "clinicaltrials_gov",
        "registryName": "ClinicalTrials.gov",
        "license": "public-domain",
        "sourceId": "NCT03392909",
        "sourceUrl": "https://clinicaltrials.gov/study/NCT03392909",
        "sourceStatus": "UNKNOWN",
        "retrievedAt": "2026-10-20T04:33:42.344Z",
        "payloadSha256": "b765f3eae4fff6a9583606b6594a29a4b9b6d765247d24f15afbe1742c8c098e",
        "piiRedacted": true
      }
    ],
    "citation": {
      "canonicalId": "NCT03392909",
      "sources": [
        {
          "registry": "clinicaltrials_gov",
          "registryName": "ClinicalTrials.gov",
          "license": "public-domain",
          "sourceId": "NCT03392909",
          "verifyAt": "https://clinicaltrials.gov/study/NCT03392909",
          "retrievedAt": "2026-10-20T04:33:42.344Z",
          "payloadSha256": "b765f3eae4fff6a9583606b6594a29a4b9b6d765247d24f15afbe1742c8c098e",
          "text": "ClinicalTrials.gov, record NCT03392909 (https://clinicaltrials.gov/study/NCT03392909), retrieved 2026-10-20, licence: public-domain."
        }
      ],
      "crossRegistry": false,
      "dedupMethod": "exact cross-registry identifier matching; probabilistic = review only",
      "text": "Trial NCT03392909, registered in ClinicalTrials.gov, retrieved 2026-10-20. Verify at the source URLs listed; each retrieval is checksummed.",
      "note": "Only one registry is known to hold this trial. Absence from the others is not evidence it was not registered there."
    },
    "provenanceNote": "Personal contact fields (names, emails, phone numbers, addresses) are stripped from every stored payload. No participant-level data is collected or served."
  },
  "_meta": {
    "api": "The Last Economy Wire: World Trials API",
    "version": "1.0",
    "schemaVersion": "1",
    "correlationId": "req_iLld-blk9unh",
    "generatedAt": "2026-10-30T22:25:44.806Z",
    "documentation": "https://negativeresistance.com/embed",
    "license": "Free for any use. Attribution appreciated.",
    "degraded": false,
    "provenance": {
      "sources": [
        "clinicaltrials_gov"
      ],
      "attribution": {
        "clinicaltrials_gov": "ClinicalTrials.gov: licence: public-domain, https://clinicaltrials.gov/data-api/api-docs"
      },
      "dedupMethod": "exact cross-registry identifier matching; probabilistic = review only",
      "limitations": [],
      "provenanceEndpoint": "/api/v1/sources"
    },
    "freshness": {
      "newestEvidenceAt": null,
      "lastSyncedAt": {
        "clinicaltrials_gov": "2026-10-28T04:33:30.663Z"
      },
      "degradedSources": [],
      "worldwide": false,
      "maxAgeHours": 65.9,
      "fromCache": false
    },
    "links": {
      "discovery": "https://negativeresistance.com/api/v1",
      "openapi": "https://negativeresistance.com/api/v1/openapi.json",
      "mcp": "https://negativeresistance.com/api/v1/mcp",
      "agentCard": "https://negativeresistance.com/.well-known/agent.json",
      "aiPlugin": "https://negativeresistance.com/.well-known/ai-plugin.json",
      "sdk": "https://negativeresistance.com/api/v1/sdk",
      "status": "https://negativeresistance.com/api/v1/status",
      "provenance": "https://negativeresistance.com/api/v1/sources",
      "contract": "https://negativeresistance.com/api/v1/contract",
      "curriculum": "https://negativeresistance.com/api/v1/curriculum",
      "graph": "https://negativeresistance.com/api/v1/graph",
      "openQuestions": "https://negativeresistance.com/api/v1/open-questions",
      "scoreboard": "https://negativeresistance.com/api/v1/scoreboard",
      "findings": "https://negativeresistance.com/api/v1/findings",
      "claims": "https://negativeresistance.com/api/v1/claims",
      "threads": "https://negativeresistance.com/api/v1/threads",
      "assignment": "https://negativeresistance.com/api/v1/assignment",
      "changes": "https://negativeresistance.com/api/v1/changes",
      "hello": "https://negativeresistance.com/api/v1/hello",
      "errors": "https://negativeresistance.com/api/v1/errors",
      "webhooks": "https://negativeresistance.com/api/v1/webhooks",
      "a2a": "https://negativeresistance.com/api/v1/a2a",
      "deadEnds": "https://negativeresistance.com/api/v1/dead-ends",
      "decompositions": "https://negativeresistance.com/api/v1/decompositions",
      "rungs": "https://negativeresistance.com/api/v1/rungs",
      "methods": "https://negativeresistance.com/api/v1/methods",
      "reality": "https://negativeresistance.com/api/v1/reality",
      "council": "https://negativeresistance.com/api/v1/council",
      "calibration": "https://negativeresistance.com/api/v1/calibration",
      "freshness": "https://negativeresistance.com/api/v1/freshness",
      "mission": "https://negativeresistance.com/api/v1/mission",
      "twin": "https://negativeresistance.com/api/v1/twin",
      "twinExperiment": "https://negativeresistance.com/api/v1/twin/experiment",
      "betaCell": "https://negativeresistance.com/api/v1/twin/beta-cell",
      "patientModel": "https://negativeresistance.com/api/v1/twin/patient-model",
      "agentCardCanonical": "https://negativeresistance.com/.well-known/agent-card.json",
      "collaborate": "https://negativeresistance.com/collaborate",
      "manifesto": "https://negativeresistance.com/about",
      "documentation": "https://negativeresistance.com/embed",
      "connect": "https://negativeresistance.com/connect",
      "llmsTxt": "https://negativeresistance.com/llms.txt",
      "llmsFullTxt": "https://negativeresistance.com/llms-full.txt"
    },
    "disclaimer": "Research data from public registries and literature; not medical advice."
  }
}